Low-VA-RNA AAV Producer Cells for Scalable Capsid Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV-based production systems lack scalability, robustness, and reproducibility, requiring transient transfection and helper viruses, leading to high costs and extensive purification processes.
Innovation Solution
Inactivate the protein kinase R (PKR) activating sequence surrounding the start codon of AAV capsid protein VP1 by replacing the native promoter and intron with a different promoter and intron, such as SV40, to maintain functional expression of VP1, VP2, and VP3, and integrate essential components into host cells without VA RNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transient transfection with helper viruses is used for AAV production, then AAV can be produced with functional expression of capsid proteins, but the production system lacks scalability, robustness, and reproducibility, and requires extensive purification processes
Solution Approach 1:
The invention extracts and removes the harmful VA RNA component from the production system. By using host cells that do not express VA RNA, the system eliminates the need for helper viruses and the associated extensive purification processes, while maintaining reliable AAV production
Solution Approach 2:
The host cells are engineered to provide all necessary components for AAV production autonomously. The cells contain integrated AAV genome, replicase, and capsid genes, and can produce AAV without requiring external helper viruses or VA RNA,实现ing self-sufficient production
2Productivity
If helper viruses are added during AAV production, then AAV production can proceed, but extensive purification is required to remove helper viruses from the final product, increasing costs and complexity
Solution Approach 1:
The invention removes the requirement for helper viruses by using host cells that do not express VA RNA. This extraction of the harmful dependency eliminates the need for extensive purification to remove helper viruses from the final AAV product
Solution Approach 2:
The invention introduces a modified capsid protein sequence as an intermediary that prevents PKR activation. This intermediary element allows the system to function without VA RNA and helper viruses, eliminating purification losses
3Reliability
If VA RNA is expressed at high levels to suppress PKR activation, then capsid protein expression is maintained, but the production system becomes less scalable and more costly
Solution Approach 1:
The invention extracts the harmful dependency on high-level VA RNA expression. By using host cells that do not express VA RNA and employing modified capsid sequences that resist PKR activation, the system achieves reliable capsid protein expression without the scalability limitations imposed by VA RNA production requirements
Solution Approach 2:
The invention changes the biochemical parameters of the capsid protein by modifying the sequence surrounding the start codon. This parameter change makes the capsid protein resistant to PKR activation, allowing reliable expression without high-level VA RNA and enabling scalable production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables stable, scalable, and reproducible AAV production with low VA RNA expression, eliminating the need for helper viruses and reducing production costs, while ensuring high titer and consistent product quality.
Implementation Method 1
the protein kinase R (PKR) activating sequence surrounding the start codon of AAV capsid protein VP1 is inactivated, while maintaining functional expression of the AAV capsid proteins VP1, VP2, and VP3
Data Source
AI summary
The present invention relates to host cells comprising a nucleic acid encoding an Adeno-associated virus (AAV) capsid protein, wherein the protein kinase R (PKR) activating sequence surrounding the start codon of AAV capsid protein VP1 is inactivated, while maintaining functional expression of the AAV capsid proteins VP1, VP2, and VP3. The present invention further relates to methods for the production of Adeno-associated virus (AAV), comprising the step of expressing said AAV in the host cells of the present invention.